关于PRMT1调节器的概述:抑制剂和降解剂
Junwei Wu1, Deping Li2, Lifang Wang1
1Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, 341000, China.
European journal of medicinal chemistry
|September 24, 2024
概括
蛋白质氨酸甲基转移酶1 (PRMT1) 对细胞功能至关重要,并与癌症有关. 本综述探讨了PRMT1的情况.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 蛋白质氨酸甲基转移酶1 (PRMT1) 对于正常的细胞功能至关重要.
- 失调的PRMT1表达与瘤开始,进展和患者预后相关.
- PRMT1在转录调节,信号转导和DNA修复中发挥关键作用.
研究的目的:
- 审查PRMT1.1的结构,生物功能和癌症相关性.
- 总结PRMT1调节器设计和开发用于癌症治疗的最新进展.
- 讨论基于PRMT1的抗癌药物发现的挑战和未来方向.
主要方法:
- 关于PRMT1结构,功能和癌症相关性的文献综述.
- 对PRMT1调制剂 (抑制剂,PROTACs) 的最新发展进行分析.
- 评估PRMT1向剂的合理设计,药理动力学,药理动力学和临床状态.
主要成果:
- 在瘤学中,PRMT1是经过验证的治疗点.
- 目前正在开发各种PRMT1调节剂,包括异型选择性抑制剂和PROTAC降解剂.
- 药物开发的关键考虑因素包括合理设计,PK/PD和临床疗效.
结论:
- 在新型癌症治疗中,PRMT1是一个有前途的标.
- 对PRMT1调节器的持续研究具有改善癌症治疗结果的巨大潜力.
- 解决当前的挑战将为基于PRMT1的有效药物发现铺平道路.
相关概念视频
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K
Regulation of Expression at Multiple Steps
875
The gene expression in cells is regulated at different stages: (i) transcription, (ii) RNA processing, (iii) RNA localization, and (iv) translation. Transcriptional regulation is mediated by regulatory proteins such as transcription factors, activators, or repressors—these control gene expression by initiating or inhibiting the transcription of genes. Once a precursor or pre-mRNA is produced, it undergoes post-transcriptional modification, including 5' capping, splicing, and the...
875
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
159
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
159
Antidepressant Drugs: MAOIs and Other Agents
201
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
201
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Regulated Protein Degradation
2.5K
2.5K


